Harvard Bioscience Stock Performance
| HBIO Stock | USD 0.44 0.01 2.22% |
Harvard Bioscience holds a performance score of 5 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.88, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Harvard Bioscience will likely underperform. Use Harvard Bioscience value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Harvard Bioscience.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Harvard Bioscience are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating forward indicators, Harvard Bioscience displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4.3 M | |
| Total Cashflows From Investing Activities | -1.3 M |
Harvard Bioscience Relative Risk vs. Return Landscape
If you would invest 39.00 in Harvard Bioscience on April 24, 2025 and sell it today you would earn a total of 5.00 from holding Harvard Bioscience or generate 12.82% return on investment over 90 days. Harvard Bioscience is currently generating 1.4011% in daily expected returns and assumes 19.7655% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Harvard, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Harvard Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Harvard Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Harvard Bioscience, and traders can use it to determine the average amount a Harvard Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0709
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | HBIO | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 19.77 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.4 actual daily | 28 72% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Harvard Bioscience is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Harvard Bioscience by adding it to a well-diversified portfolio.
Harvard Bioscience Fundamentals Growth
Harvard Stock prices reflect investors' perceptions of the future prospects and financial health of Harvard Bioscience, and Harvard Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Harvard Stock performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.0238 | ||||
| Profit Margin | (0.64) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 59 M | ||||
| Shares Outstanding | 44.21 M | ||||
| Price To Earning | (25.00) X | ||||
| Price To Book | 1.34 X | ||||
| Price To Sales | 0.22 X | ||||
| Revenue | 94.14 M | ||||
| EBITDA | (1.47 M) | ||||
| Cash And Equivalents | 4.26 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 44.49 M | ||||
| Debt To Equity | 0.73 % | ||||
| Book Value Per Share | 0.34 X | ||||
| Cash Flow From Operations | 1.44 M | ||||
| Earnings Per Share | (1.31) X | ||||
| Total Asset | 126.64 M | ||||
| Retained Earnings | (158.01 M) | ||||
| Current Asset | 50.55 M | ||||
| Current Liabilities | 19.32 M | ||||
About Harvard Bioscience Performance
By examining Harvard Bioscience's fundamental ratios, stakeholders can obtain critical insights into Harvard Bioscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Harvard Bioscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company was founded in 1901 and is headquartered in Holliston, Massachusetts. Harvard Bioscience operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 475 people.Things to note about Harvard Bioscience performance evaluation
Checking the ongoing alerts about Harvard Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Harvard Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Harvard Bioscience is way too risky over 90 days horizon | |
| Harvard Bioscience has some characteristics of a very speculative penny stock | |
| Harvard Bioscience appears to be risky and price may revert if volatility continues | |
| Harvard Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 94.14 M. Net Loss for the year was (12.4 M) with profit before overhead, payroll, taxes, and interest of 52.22 M. | |
| About 70.0% of the company shares are owned by institutional investors |
- Analyzing Harvard Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Harvard Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Harvard Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Harvard Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Harvard Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Harvard Bioscience's stock. These opinions can provide insight into Harvard Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.